HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chronix Biomedical appoints new chairman

This article was originally published in Clinica

Executive Summary

Chronix Biomedical, a company developing serum DNA-based blood tests to detect and manage cancer, has made Paul Freiman chairman of the board. Mr Freiman has over 30 years' experience in the pharmaceutical and biotech industry, including as CEO of Syntex and Neurobiological Technologies. He also serves on the board of Penwest Pharmaceuticals, Otsuka America Pharmaceuticals and NeoPharm. San Jose, California-based Chronix is developing blood tests that analyse DNA released into the blood by damaged and dying cells. They are designed to detect cancer at its earliest stages and track patients' responses to treatment. The company is currently advancing its technology through clinical validation towards commercialisation, and is seeking partners for further development.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel